Annual CFO
-$18.65 M
+$2.27 M+10.87%
December 31, 2023
Summary
- As of February 12, 2025, CRDL annual cash flow from operations is -$18.65 million, with the most recent change of +$2.27 million (+10.87%) on December 31, 2023.
- During the last 3 years, CRDL annual CFO has fallen by -$11.83 million (-173.69%).
- CRDL annual CFO is now -1770.28% below its all-time high of -$997.10 thousand, reached on December 1, 2017.
Performance
CRDL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$5.72 M
-$2.30 M-67.47%
September 30, 2024
Summary
- As of February 12, 2025, CRDL quarterly cash flow from operations is -$5.72 million, with the most recent change of -$2.30 million (-67.47%) on September 30, 2024.
- Over the past year, CRDL quarterly CFO has dropped by -$2.30 million (-67.47%).
- CRDL quarterly CFO is now -2032.10% below its all-time high of -$268.20 thousand, reached on March 1, 2018.
Performance
CRDL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$18.97 M
-$3.15 M-19.89%
September 30, 2024
Summary
- As of February 12, 2025, CRDL TTM cash flow from operations is -$18.97 million, with the most recent change of -$3.15 million (-19.89%) on September 30, 2024.
- Over the past year, CRDL TTM CFO has dropped by -$3.15 million (-19.89%).
- CRDL TTM CFO is now -6972.48% below its all-time high of -$268.20 thousand, reached on March 1, 2018.
Performance
CRDL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CRDL Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.9% | -67.5% | -19.9% |
| 3 y3 years | -173.7% | -67.5% | -19.9% |
| 5 y5 years | -121.8% | -67.5% | -19.9% |
CRDL Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +10.9% | -429.6% | +41.0% | -30.8% | +19.7% |
| 5 y | 5-year | -173.7% | +10.9% | -618.9% | +41.0% | -190.2% | +19.7% |
| alltime | all time | -1770.3% | +10.9% | -2032.1% | +41.0% | -6972.5% | +19.7% |
Cardiol Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.72 M(+67.5%) | -$18.97 M(+19.9%) |
| Jun 2024 | - | -$3.41 M(-33.5%) | -$15.82 M(-3.7%) |
| Mar 2024 | - | -$5.13 M(+9.1%) | -$16.43 M(-11.9%) |
| Dec 2023 | -$18.65 M(-10.9%) | -$4.70 M(+82.9%) | -$18.65 M(-21.1%) |
| Sep 2023 | - | -$2.57 M(-36.1%) | -$23.63 M(+6.7%) |
| Jun 2023 | - | -$4.02 M(-45.3%) | -$22.14 M(+10.4%) |
| Mar 2023 | - | -$7.35 M(-24.1%) | -$20.06 M(-4.1%) |
| Dec 2022 | -$20.92 M(+11.4%) | -$9.68 M(+796.8%) | -$20.92 M(+44.3%) |
| Sep 2022 | - | -$1.08 M(-44.4%) | -$14.50 M(-20.4%) |
| Jun 2022 | - | -$1.94 M(-76.4%) | -$18.22 M(-14.9%) |
| Mar 2022 | - | -$8.22 M(+152.2%) | -$21.40 M(+14.0%) |
| Dec 2021 | -$18.78 M | - | - |
| Dec 2021 | - | -$3.26 M(-32.1%) | -$18.78 M(+8.0%) |
| Sep 2021 | - | -$4.80 M(-6.3%) | -$17.38 M(+16.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$5.12 M(-8.3%) | -$14.92 M(+40.9%) |
| Mar 2021 | - | -$5.59 M(+199.8%) | -$10.59 M(+55.4%) |
| Dec 2020 | -$6.81 M(-20.5%) | -$1.86 M(-20.4%) | -$6.81 M(-5.7%) |
| Sep 2020 | - | -$2.34 M(+194.5%) | -$7.22 M(+10.5%) |
| Jun 2020 | - | -$795.40 K(-56.1%) | -$6.54 M(-10.9%) |
| Mar 2020 | - | -$1.81 M(-20.4%) | -$7.34 M(-14.4%) |
| Dec 2019 | -$8.57 M(+2.0%) | -$2.27 M(+37.4%) | -$8.57 M(-33.2%) |
| Sep 2019 | - | -$1.66 M(+3.8%) | -$12.83 M(+3.7%) |
| Jun 2019 | - | -$1.60 M(-47.7%) | -$12.37 M(+10.6%) |
| Mar 2019 | - | -$3.05 M(-53.3%) | -$11.19 M(+33.1%) |
| Dec 2018 | -$8.41 M(+743.1%) | -$6.53 M(+444.4%) | -$8.41 M(+347.5%) |
| Sep 2018 | - | -$1.20 M(+191.7%) | -$1.88 M(+176.5%) |
| Jun 2018 | - | -$411.10 K(+53.3%) | -$679.30 K(+153.3%) |
| Mar 2018 | - | -$268.20 K | -$268.20 K |
| Dec 2017 | -$997.10 K | - | - |
FAQ
- What is Cardiol Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Cardiol Therapeutics?
- What is Cardiol Therapeutics annual CFO year-on-year change?
- What is Cardiol Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cardiol Therapeutics?
- What is Cardiol Therapeutics quarterly CFO year-on-year change?
- What is Cardiol Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Cardiol Therapeutics?
- What is Cardiol Therapeutics TTM CFO year-on-year change?
What is Cardiol Therapeutics annual cash flow from operations?
The current annual CFO of CRDL is -$18.65 M
What is the all time high annual CFO for Cardiol Therapeutics?
Cardiol Therapeutics all-time high annual cash flow from operations is -$997.10 K
What is Cardiol Therapeutics annual CFO year-on-year change?
Over the past year, CRDL annual cash flow from operations has changed by +$2.27 M (+10.87%)
What is Cardiol Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CRDL is -$5.72 M
What is the all time high quarterly CFO for Cardiol Therapeutics?
Cardiol Therapeutics all-time high quarterly cash flow from operations is -$268.20 K
What is Cardiol Therapeutics quarterly CFO year-on-year change?
Over the past year, CRDL quarterly cash flow from operations has changed by -$2.30 M (-67.47%)
What is Cardiol Therapeutics TTM cash flow from operations?
The current TTM CFO of CRDL is -$18.97 M
What is the all time high TTM CFO for Cardiol Therapeutics?
Cardiol Therapeutics all-time high TTM cash flow from operations is -$268.20 K
What is Cardiol Therapeutics TTM CFO year-on-year change?
Over the past year, CRDL TTM cash flow from operations has changed by -$3.15 M (-19.89%)